Ignite Creation Date:
2024-05-05 @ 4:42 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00294866
Status:
COMPLETED
Last Update Posted:
2010-04-08
First Post:
2006-02-17
Brief Title:
Effect of Paricalcitol on Markers of Inflammation in Hemodialysis Patients
Sponsor:
Fresenius Medical Care North America
Organization:
Fresenius Medical Care North America
Study Overview
Official Title:
An Open Label Multi-Center Study of the Effect of Paricalcitol on Markers of Inflammation in Patients With Stage 5 Chronic Kidney Disease on Hemodialysis
Status:
COMPLETED
Status Verified Date:
2010-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Studies have shown that patients with ESRD on hemodialysis have high levels of inflammatory markers which may contribute to the high rates of cardiovascular disease and mortality seen in these patients Vitamin D use in dialysis patients has been shown to have a survival benefit with paricalcitol at advantage over calcitriol Since there is some evidence for involvement of the vitamin D receptor in inflammation this study is designed to look for an effect of paricalcitol on markers of inflammation in hemodialysis patients
Detailed Description:
Patients with ESRD have a high incidence of acute phase inflammation Studies have shown that C-reactive Protein CRP and interleukin-6 IL-6 are excellent biomarkers for inflammation and high levels are predictive of cardiovascular morbidity and mortality in this population Both uremia and the dialysis process itself contribute to this inflammatory state It is our hypothesis that paricalcitol therapy decreases the biomarkers of inflammation which may have implications for future studies of morbidity and mortality in this population
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None